The Most Undervalued Relationship in Clinical Trials—and How Technology Can Determine Its Success

By Susan Najjar

Clinical trials are built on protocols, powered by data, and governed by compliance. But according to Steve Rosenberg, CEO of uMotif and a veteran of clinical trial technology, they succeed—or fail—on something far more human: the relationship between the patient and the site. That perspective may sound obvious. Yet the industry has spent decades optimizing everything except that relationship.
​
Patients Are Not “Subjects”—They Are the Heroes

Rosenberg’s view is candid and difficult to ignore: patients are the heroes of clinical research.
They sacrifice time, comfort, and often physical well-being. Some enroll because it is their last option. Others participate to “pay it forward” for future patients. And yet, until recently, industry language lumped them into the same category as lab animals--subjects.

In an era where endpoints increasingly rely on patient reported outcomes (PROs), quality of life measures, and real-world experience, failing to fully recognize and support patients is a miss on pharma’s part.
More data than ever is coming directly from patients. If they disengage, misunderstand, or drop out, the trial is at risk of losing participation.

Why the Patient–Site Relationship Matters Most

Ask patients who they trust in a clinical trial, and most won’t name the sponsor. They may not even know who it is. They trust the investigator, the study coordinator, the nurse—the people guiding them through consent, screening, and day-to-day participation. That trust is what drives compliance, retention, and honest reporting.

This becomes even more critical in rare disease trials, where patient populations are small and every participant carries significant scientific and financial value. When a single patient drops out, the cost can reach hundreds of thousands of dollars—and the loss of irreplaceable data.

So Why Do Trials Still Fail to Prioritize Patients?

It’s not deliberate. It’s complexity. By the time a protocol reaches a site, it has already passed through a maze of manufacturing logistics, global supply chains, regulatory approvals, translations, device provisioning, and statistical planning. Amid all of that operational pressure, the patient becomes abstract—a checkbox rather than a person with a family, a job, and a life disrupted by disease.

Technology has historically made this worse. Most trial tools were designed top-down, forcing patients into rigid workflows: provisioned devices, unfamiliar interfaces, mandatory questionnaires, often delivered with little  context, or  gratitude expressed for participation Compliance was expected, not earned.

Technology Should Be Invisible—and Human

Rosenberg argues that good technology should disappear into the background. Patients shouldn’t wake up thinking about systems, platforms, or validations. They should think, “I need to answer a few questions today,” tap a reminder, and move on with their lives.

Modern clinical trial technology must behave like consumer technology—not clinical machinery.
At uMotif, that philosophy means:

• Bring-your-own-device experiences that feel like everyday apps
• Thoughtful reminders and nudges, not blunt demands
• Clear, interactive eConsent that builds understanding and trust
• Simple, intuitive interfaces that respect patients’ time

Validation and compliance  matter. But how patients experience those requirements determines whether the data are reliable.

Measuring What Trials Usually Ignore

One of the most overlooked drivers of dropout isn’t adverse events—it’s life friction.
Parking. Transportation. Time off work. Feeling undervalued. Rosenberg recounts a moment that stunned a room full of cancer researchers: the number one reason patients declined trial participation wasn’t fear or side effects—it was parking.That insight reshapes how we think about “patient centricity.” It’s not just about endpoints and outcomes; it’s about logistics, dignity, and support.

Capturing non-clinical signals--Do you feel valued? Is this creating financial hardship? Are you getting what you need?—can provide early warning long before a patient disengages completely.
In rare disease trials especially, that foresight can make or break a program.

The Biggest Myth: Patient-Centric Trials Cost More

They don’t. According to Rosenberg, patient centricity is a mindset problem, not a budget problem. Designing trials around patients doesn’t inherently require more money—it requires different priorities.
In fact, the economics often favor patient-first design:

• Fewer dropouts
• Higher compliance
• Better data quality
• Faster timelines
• Stronger word-of-mouth for future trials

The Takeaway for Biotech and Pharma Leaders

As endpoints shift toward lived experience and trials become more decentralized and patient-driven, the industry faces a choice: Continue optimizing systems for protocols—or design trials for people.
The science demands the latter.